NICE recommends rivaroxaban for stroke prevention in AF

on the 21 June 2012

Rivaroxaban (Xarelto) has been approved by NICE for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).

Xarelto (rivaroxaban) is taken orally once daily with food and does not require regular anticoagulation monitoring
Xarelto (rivaroxaban) is taken orally once daily with food and does not require regular anticoagulation monitoring
The anticoagulant can be used in patients with non-valvular AF with one or more of the following risk factors:
•    Previous stroke or transient ischaemic attack
•    Congestive heart failure
•    Age 75 years or older
•    Diabetes
•    Hypertension.

Rivaroxaban is also recommended by NICE at a lower dose for the prevention of venous thromboembolism following elective total hip or knee replacement surgery.            

Further details
NICE guidance on rivaroxaban in atrial fibrillation

Further information:
View Xarelto drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Reversal of benefits after novel migraine prophylactics stopped, study shows

Reversal of benefits after novel migraine prophylactics stopped, study shows

Findings from a recent study indicate a return to pre-treatment...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...